Regeneron Pharmaceuticals, Inc.
Close on Nov 19, 2026Market cap $95.52BP/E 20.4Yield –
Regeneron Pharmaceuticals Net Product Sales Recorded by Regeneron
Net Product Sales Recorded by Regeneron ($M) ($M)
Regeneron Pharmaceuticals Net Product Sales Recorded by Regeneron: $1,805M in Q3 2026, up 13.7% from a year earlier.
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Note 2.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Product Sales Recorded by Regeneron ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 1,805 | +13.7% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2026 | Jun 30, 2026 | 1,642 | +0.7% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,535 | +8.4% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,675 | -16.4% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,588 | -18.4% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,631 | -15.0% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,416 | -19.6% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,003 | +8.2% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,946 | +9.0% | Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,919 | +8.3% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,761 | +5.6% | Form 10-Q (filed 2025-04-29) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,852 | +9.0% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,786 | -0.8% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,772 | +1.0% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,668 | +1.8% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,699 | -57.3% | Form 10-K (filed 2025-02-05) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,801 | -21.0% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,754 | -57.6% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,639 | -5.0% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 3,975 | +145.1% | Form 10-K (filed 2024-02-05) ↗ |
| Q3 2021 | Sep 30, 2021 | 2,280 | +53.8% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 4,138 | +237.3% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,724 | +39.4% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,622 | +26.1% | Form 10-K (filed 2023-02-06) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,482 | +19.7% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,227 | +1.8% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,237 | +12.0% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,286 | +17.3% | Form 10-K (filed 2022-02-07) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,238 | +20.8% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,205 | +21.0% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,104 | +11.8% | Form 10-Q (filed 2020-05-05) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,096 | +12.0% | Form 10-K (filed 2021-02-08) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,026 | +7.1% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 996 | +7.8% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 988 | – | Form 10-Q (filed 2019-05-07) ↗ |
| Q4 2017 | Dec 31, 2017 | 979 | – | Form 10-K (filed 2020-02-07) ↗ |
| Q3 2017 | Sep 30, 2017 | 957 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 924 | – | Form 10-Q (filed 2018-08-02) ↗ |
Breakdown
What makes up net Product Sales Recorded by Regeneron
- Net Product Sales Recorded by Regeneron YoY Growth (%)14.0% · Q3 2026
- EYLEA HD & EYLEA Total — U.S. Net Product Sales ($M)1,099 · Q3 2026
- Libtayo — Global Net Product Sales Recorded by Regeneron ($M)550 · Q3 2026
- Praluent — U.S. Net Product Sales Recorded by Regeneron ($M)81.5 · Q3 2026
- Evkeeza — U.S. Net Product Sales Recorded by Regeneron ($M)55.5 · Q3 2026
- Lynozyfic — Global Net Product Sales Recorded by Regeneron ($M)19 · Q3 2026
- Other Net Product Sales Recorded by Regeneron (Inmazeb, Veopoz) ($M)0.80 · Q3 2026
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Net Product Sales Recorded by Regeneron ($M), quarterly Q2 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-prod-total
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?